During biologics discovery the ability to evaluate antigen-antibody interactions via multiplexed binding assays at high throughput provides more comprehensive information in the primary screening phase. Identifying hits by simultaneous evaluation of specificity and cross-reactivity builds confidence in potential hits, and increases the likelihood that candidate molecules will successfully proceed through downstream steps in the discovery and development process.
This on-demand webinar features two user talks that demonstrate how the Intellicyt® iQue Screener platform enhanced productivity in their biologics discovery workflow.
- Yana Wang, Ph.D., from Takeda Pharmaceuticals, highlights multiplexing multiple cell lines of interest in one well to simultaneously quantitate on-target activity, cross-reactivity and non-specific activity along with measurement of antibody concentration using, the Intellicyt iQue Screener PLUS platform. The ability to measure multiple parameters coupled with the platform’s speed and increased accuracy provides gains in productivity and helps accelerate antibody discovery.
- Robert Ford, Ph.D., from Avacta Life Sciences, provides an overview of novel Anti-idiotpyic Affimer® reagents and their importance in the bioanalysis of therapeutic antibody drug candidates and demonstrates how these Affimer® reagents are identified using the Intellicyt iQue Screener platform by incorporating cross-reactivity profiling against similar antibody drug candidates into the primary screening phase of the discovery process.
Yana Wang, Ph.D.,
Scientist, Takeda Pharmaceuticals
Robert Ford, Ph.D.,
Senior Scientist, Avacta Life Sciences
Complete the form to watch this webinar on-demand.